MBE Wealth Management LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,039 shares of the company’s stock, valued at approximately $136,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of JNJ. Tamarack Advisers LP purchased a new position in Johnson & Johnson during the fourth quarter valued at $18,035,000. Orser Capital Management LLC grew its stake in Johnson & Johnson by 44.2% during the fourth quarter. Orser Capital Management LLC now owns 1,875 shares of the company’s stock valued at $272,000 after acquiring an additional 575 shares in the last quarter. Exchange Traded Concepts LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at $31,000. Arkfeld Wealth Strategies L.L.C. bought a new position in Johnson & Johnson during the fourth quarter valued at $536,000. Finally, SeaCrest Wealth Management LLC lifted its position in Johnson & Johnson by 5.8% during the fourth quarter. SeaCrest Wealth Management LLC now owns 49,644 shares of the company’s stock valued at $7,241,000 after purchasing an additional 2,718 shares during the last quarter. 67.66% of the stock is owned by institutional investors.

In related news, Director William D. Perez acquired 500 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average price of $127.69 per share, for a total transaction of $63,845.00. Following the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at approximately $2,046,870.70. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.27% of the company’s stock.

Several equities analysts have commented on JNJ shares. Credit Suisse Group reiterated a “buy” rating and set a $161.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, April 28th. Argus reiterated a “buy” rating and set a $155.00 price objective (down previously from $165.00) on shares of Johnson & Johnson in a research report on Friday, March 27th. Bank of America upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the company from $150.00 to $175.00 in a research report on Wednesday, April 22nd. UBS Group lowered shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $163.00 to $160.00 in a research report on Tuesday, April 28th. Finally, Morgan Stanley increased their price objective on shares of Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $163.47.

Johnson & Johnson stock opened at $144.37 on Friday. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The firm has a 50-day moving average price of $146.81 and a 200-day moving average price of $142.30. The firm has a market capitalization of $386.52 billion, a PE ratio of 19.10, a price-to-earnings-growth ratio of 3.19 and a beta of 0.71. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The company had revenue of $20.69 billion during the quarter, compared to analyst estimates of $19.48 billion. During the same quarter last year, the business posted $2.10 EPS. The firm’s revenue for the quarter was up 3.3% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 7.68 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a dividend of $1.01 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.95. The ex-dividend date is Friday, May 22nd. This represents a $4.04 dividend on an annualized basis and a yield of 2.80%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 43.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: How to interpret Moving Average Convergence Divergence (MACD)

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.